Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the challenges and advancements in treating acute myeloid leukemia (AML) in patients who are unfit for intensive…
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a study evaluating the efficacy of combining venetoclax with hypomethylating agents in treating patients with acute myeloid leukemia…
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, reports recent findings from a study using pembrolizumab and lenvatinib as a second-line treatment for clear cell…
Suresh Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, addresses autoimmune toxicities associated with combination immune therapies as in the CheckMate-227 trial for non-small cell…
Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, addresses the need for additional predictive biomarkers for non-small cell…
Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California San Diego, discusses the PDIGREE study design for the treatment of renal…
Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the…
Guidelines from the American Society of Hematology (ASH) review panel recommend standards of care for individualized acute myeloid leukemia (AML) treatments. For patients with newly diagnosed AML, ASH…
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for…
The American Society of Hematology (ASH) has released 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults. Specifically, the guidelines help patients and doctors…
Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation…
Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center – James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved…
